Phase 1 CRD3874-SI allosteric STING agonist (TMEM173) in relapsed/refractory AML.

This Memorial Sloan Kettering Cancer Center–sponsored Phase 1 study tests escalating dose levels of CRD3874-SI, an intravenous small-molecule STING (TMEM173) agonist designed to activate innate immune signaling and drive type I interferon–linked anti-leukemia immune effects. The trial’s main goal is safety/tolerability and selection of a biologically effective dose / recommended Phase 2 dose in adults with relapsed or refractory AML who have failed therapies known to be active for their AML. The intervention is CRD3874-SI monotherapy across multiple dose cohorts. The scientific angle is “next-generation” systemic STING activation: CRD3874-class agents are described as allosteric STING agonists, with preclinical/early clinical rationale aimed at preserving immune activation while mitigating toxicity seen with earlier STING agonist approaches. In this population, today’s care is still largely sequential salvage regimens (e.g., venetoclax-based combinations when feasible, targeted agents for actionable mutations such as FLT3 or IDH1/2, and allogeneic transplant for eligible responders), so the study explores an immune-innate activation strategy outside classic cytotoxic or mutation-targeted paradigms.